Company intelligence / Profile preview

Natrogen Therapeutics International, Inc.

New York, New York, United Statesnatrogen.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

NTI‑528, an AHR modulator small molecule drug, has reached Phase 2 clinical trials targeting inflammatory bowel diseases. Another compound, Meisoindigo, appears to be under development for severe active ulcerative colitis but has not yet advanced past the pending stage. The company also holds patents on isoindigo derivatives with potential applications in cancer and broader inflammatory conditions.

Therapeutic areas: GastroenterologyOncologyImmunology
Modalities: Small molecules (notably isoindigo derivatives such as Meisoindigo and NATURA)
Industry: Biotech

Beyond the preview

Go deeper on Natrogen Therapeutics International, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natrogen Therapeutics International, Inc..